查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球基因基因测试市场：按产品类型、按样本类型、按技术、按基因测试类型、按应用领域、按地区、竞争格局 - 分析与预测（2024-2033）
市场调查报告书
商品编码
1520631

全球基因基因测试市场：按产品类型、按样本类型、按技术、按基因测试类型、按应用领域、按地区、竞争格局 - 分析与预测（2024-2033）

Global Hereditary Genetic Testing Market: Focus on Product, Sample Type, Technology, Genetic Testing Type, Application Area, Region, and Competitive Landscape - Analysis and Forecast, 2024-2033
出版日期: | 出版商: BIS Research | 英文 113 Pages | 商品交期: 1-5个工作天内

价格

2023年全球基因基因检测市场规模为247.8亿美元。

预计到2033年，该市场将快速成长至819.5亿美元，2024年至2033年复合年增长率高达12.73%。在持续技术进步的推动下，市场正在经历两位数的成长。次世代定序(NGS) 等基因定序技术的创新使基因检测变得更加准确、高效且更具成本效益。公众和医疗保健专业人员对基因检测在遗传性疾病诊断和管理方面的益处的认识不断提高，导致需求增加。遗传性疾病和遗传性癌症盛行率的上升进一步加剧了对早期诊断和个人化治疗方案的需求。基因检测的广泛应用，包括产前筛检、新生儿筛检、肿瘤学和个人化医疗，正在扩大市场范围。监管支援和有利的指导方针确保基因检测的品质和可靠性，推动市场成长。

主要市场统计数据
预测期 2024-2033
2024年评估 278.8亿美元
2033 年预测 819.5亿美元
复合年增长率 12.73%

由于战略联盟和创新技术的进步，基因检测领域正在迅速发展。由柯尼卡美能达公司 (Ambry Genetics)主导的跨组织癌症遗传学临床证据联盟 (INTERACT) 合作等倡议对于促进遗传性癌症检测的普及至关重要，Incorporated 和Broad Clinical Labs 等Quest Diagnostics 合作伙伴正在证明全基因测序（WGS）在诊断产后发育迟缓障碍的临床效用。此外，我们也增强了全面的细胞株和细胞株检测服务，例如柯尼卡美能达公司 (Ambry Genetics) 与 Tempus 之间的策略合作伙伴关係。这些进展也得到了安捷伦科技公司的 GenetiSure Dx 产后检测和美国控股实验室公司的磷酸化Tau 217 (pTau217) 独立血液生物标誌物测试等产品的核准和推出，其中每一项都是基因测试我们正在为扩大选择做出贡献。 Myriad Genetics, Inc. 收购 Intermountain Precision Genomics 等收购，为产业的持续成长和创新奠定了基础，有望透过个人化的基因见解改善医疗结果。

全球基因基因检测市场由 Agilent Technologies、Ambry Genetics、Color、CENTOGENE NV、Natera Inc.、Myriad Genetics, Inc. 和 Illumina, Inc. 等公司推动，为工业遗传学领域带来了革命性的变化。透过利用次世代定序（NGS）、聚合酵素链锁反应（PCR）和微阵列等尖端技术，这些公司能够提供肿瘤基因检测、神经基因检测和循环系统基因检测。产品这些产品范围从基于肿瘤组织的测试（如安捷伦科技公司的 SureMASTR 遗传性癌症）到基于唾液的测试（如 Color 提供的测试）。这些进步的影响延伸到研究和临床诊断，提供对多种疾病背后的遗传因素的深入了解，包括癌症、心血管疾病、神经系统疾病和罕见遗传疾病。透过将最尖端科技与广泛的疾病覆盖范围相结合，全球基因基因检测市场对该行业产生了重大影响，推动了个人化医疗和基因医疗保健的前沿发展。

该报告调查了全球基因基因检测市场，并按产品类型、样本类型、技术、基因检测类型、应用领域、地区和市场参与者提供市场概况、趋势。

目录

执行摘要

第一章 基因基因检测：产业展望

  • 基因检测现况
  • 市场足迹与未来潜力
  • 趋势：当前和未来的影响评估
  • 研发回顾
  • 市场总规模及渗透率
  • 法律和监管框架
  • 赎回场景
  • 市场动态

第二章 全球基因基因检测市场（分产品）

  • 概述
    • 套件和用品
    • 服务

第三章 全球基因基因检测市场（依样本类型）

  • 概述
    • 肿瘤组织
    • 骨髓
    • 唾液
    • 血
    • 其他的

第四章 全球基因检测市场（依技术）

  • 概述
    • 次世代定序（NGS）
    • 聚合酵素链锁反应(PCR)
    • 免疫组织化学 (IHC)
    • 原位杂交（ISH）
    • 微阵列技术
    • 其他的

第五章全球基因检测市场（依基因检测类型）

  • 概述
  • 心臟病学
  • 肿瘤学
  • 神经病学
  • 其他的

第六章 全球基因检测市场（依应用领域）

  • 概述
    • 学术研究
    • 临床诊断、监测和筛检
    • 药物发现

第7章 区域

  • 促进因素和抑制因素
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章市场－竞争基准化分析和公司概况

  • 竞争格局
  • 公司简介
    • Agilent Technologies, Inc.
    • BGI Group (Beijing Genomics Institute (BGI))
    • Centogene AG
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche Ltd
    • Illumina, Inc.
    • Konica Minolta, Inc. (Ambry Genetics)
    • Laboratory Corporation of America Holdings
    • Myriad Genetics, Inc.
    • Revvity, Inc. (PerkinElmer, Inc.)
    • Quest Diagnostics Incorporated
    • Thermo Fisher Scientific, Inc.
    • 基因检测市场的新兴企业

第9章调查方法

Product Code: BHP0930SB

Global Hereditary Genetic Testing Market Industry Overview

The global hereditary genetic testing market, initially valued at $24.78 billion in 2023, is poised for substantial growth, projected to surge to $81.95 billion by 2033, marking a remarkable compound annual growth rate (CAGR) of 12.73% over the period from 2024 to 2033. The market is witnessing double-digit growth, driven by continuous technological advancements. Innovations in genetic sequencing technologies, such as next-generation sequencing (NGS), have made genetic testing more accurate, efficient, and cost-effective. Increased awareness among the public and healthcare professionals about the benefits of genetic testing for diagnosing and managing hereditary conditions has led to higher demand. The rising prevalence of genetic disorders and hereditary cancers further fuels the need for early diagnosis and personalized treatment options. The expanding applications of genetic testing, including prenatal screening, newborn screening, oncology, and personalized medicine, are broadening the market scope. Regulatory support and favorable guidelines ensure the quality and reliability of genetic tests, facilitating market growth.

Market Introduction

KEY MARKET STATISTICS
Forecast Period2024 - 2033
2024 Evaluation$27.88 Billion
2033 Forecast$81.95 Billion
CAGR12.73%

The landscape of hereditary genetic testing is rapidly evolving, fuelled by strategic collaborations and innovative advancements in technology. Initiatives such as the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) Collaboration, led by Konica Minolta, Inc. (Ambry Genetics), are pivotal in promoting access to hereditary cancer testing, while partnerships such as that between Quest Diagnostics Incorporated and Broad Clinical Labs are demonstrating the clinical utility of whole genome sequencing (WGS) for diagnosing developmental delay disorders post-birth. Moreover, strategic alliances such as the one between Konica Minolta, Inc. (Ambry Genetics) and Tempus are enhancing the provision of comprehensive germline and somatic testing services. These developments are complemented by product approvals and launches, such as Agilent Technologies, Inc.'s GenetiSure Dx Postnatal Assay and Laboratory Corporation of America Holdings' independent blood biomarker test for phosphorylated tau 217 (pTau217), each contributing to the expanding toolkit of genetic testing options. With acquisitions such as Myriad Genetics, Inc.'s acquisition of assets from Intermountain Precision Genomics, the industry is poised for sustained growth and innovation, promising improved healthcare outcomes through personalized genetic insights.

Industrial Impact

The global hereditary genetic testing market, propelled by companies such as Agilent Technologies, Ambry Genetics, Color, CENTOGENE N.V., Natera Inc., Myriad Genetics, Inc., and Illumina, Inc., has revolutionized the landscape of industrial genetics. By utilizing advanced technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray, these companies offer a wide array of products catering to oncology genetic testing, neurology genetic testing, cardiology genetic testing, and rare disease testing, among others. These products range from tumor tissue-based tests such as SureMASTR Hereditary Cancer by Agilent Technologies to saliva-based tests such as those offered by Color. The impact of these advancements extends across research and clinical diagnostics, offering insights into hereditary factors contributing to various diseases such as cancer, cardiovascular disorders, neurological conditions, and rare genetic diseases. Through the integration of cutting-edge technologies and expansive disease coverage, the industrial impact of the global hereditary genetic testing market is profound, driving forward the frontiers of personalized medicine and genetic healthcare.

Market Segmentation:

Segmentation 1: by Product

  • Kits and Consumables
  • Services

Services Segment to Dominate the Hereditary Genetic Testing Market (by Product)

Based on product, the global hereditary genetic testing market was led by the services segment, which held a 69.33% share in 2023. This substantial market share indicates the high demand for services related to hereditary genetic testing, which includes genetic counseling, testing, and result interpretation. The prominence of the services segment highlights the importance of comprehensive support and expertise in genetic testing processes, ensuring accurate diagnosis and personalized healthcare solutions.

Segmentation 2: by Sample Type

  • Tumor Tissue
  • Bone Marrow
  • Saliva
  • Blood
  • Other Sample Types

Blood Segment to Dominate the Hereditary Genetic Testing Market (by Sample Type)

Based on sample type, the global hereditary genetic testing market was led by the blood segment, which held a 41.79% share in 2023. This dominant market share underscores the preference for blood samples in hereditary genetic testing due to their reliability and ease of collection. Blood samples provide a rich source of DNA, which is essential for accurate and comprehensive genetic analysis. The prominence of the blood segment reflects the established protocols and widespread acceptance of blood-based testing in clinical and research settings. This trend highlights the crucial role of blood samples in facilitating precise diagnosis and management of hereditary conditions, ultimately contributing to improved patient care and outcomes.

Segmentation 3: by Technology

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Microarray Techniques
  • Other Technologies

Next-Generation Sequencing Segment to Dominate the Hereditary Genetic Testing Market (by Technology)

Based on technology, the global hereditary genetic testing market was led by the next-generation sequencing segment, which held a 32.08% share in 2023. This significant market share highlights the advanced capabilities and growing adoption of NGS technology in hereditary genetic testing. NGS offers high-throughput sequencing, enabling the rapid and comprehensive analysis of multiple genes simultaneously, which is crucial for identifying a wide range of genetic mutations associated with hereditary conditions. The prominence of the NGS segment reflects its efficiency, accuracy, and cost-effectiveness, making it the preferred choice for both clinical diagnostics and research applications. This trend underscores the transformative impact of NGS on the genetic testing landscape, driving innovations and improving the detection and management of hereditary diseases.

Segmentation 4: by Oncology Genetic Testing Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma
  • Other Oncology Hereditary Genetic Testing

Breast Cancer Segment to Dominate the Hereditary Genetic Testing Market (by Oncology Genetic Testing Type)

Based on oncology genetic testing type, the global hereditary genetic testing market was led by the breast cancer segment, which held a 41.97% share in 2023. This significant market share underscores the high demand for genetic testing for breast cancer, reflecting the critical importance of early detection and risk assessment in managing this prevalent condition. Genetic testing for breast cancer, particularly for BRCA1 and BRCA2 mutations, plays a crucial role in identifying individuals at higher risk, enabling preventive measures and personalized treatment strategies.

Segmentation 5: by Cardiology Genetic Testing Type

  • Cardiomyopathy
  • Aortopathy
  • Arrhythmia
  • Other Cardiology Hereditary Genetic Testing

Cardiomyopathy Segment to Dominate the Hereditary Genetic Testing Market (by Cardiology Genetic Testing Type)

Based on cardiology genetic testing type, the global hereditary genetic testing market was led by the cardiomyopathy segment, which held a 33.47% share in 2023. This substantial market share underscores the growing recognition of the importance of genetic testing in diagnosing and managing cardiomyopathies, which are often hereditary and can lead to severe cardiac conditions if not detected early. Genetic testing for cardiomyopathies helps identify specific genetic mutations that cause various forms of the disease, facilitating early intervention, personalized treatment plans, and better management of at-risk individuals.

Segmentation 6: by Neurology Genetic Testing Type

  • Epilepsy
  • Neurodegenerative Disorders
  • Neuromuscular Disorders
  • Other Neurology Hereditary Genetic Testing

Epilepsy Segment to Dominate the Hereditary Genetic Testing Market (by Neurology Genetic Testing Type)

Based on neurology genetic testing type, the global hereditary genetic testing market was led by the epilepsy segment, which held a 35.55% share in 2023. This significant market share highlights the critical role of genetic testing in diagnosing and managing epilepsy, a neurological disorder with various hereditary forms. Genetic testing for epilepsy helps identify specific genetic mutations that can influence the condition, enabling more accurate diagnoses and the development of personalized treatment plans. The dominance of the epilepsy segment reflects the growing importance of genetic insights in understanding the underlying causes of epilepsy, leading to improved patient care and outcomes.

Segmentation 7: by Other Genetic Testing Type

  • Newborn Screening
  • Prenatal Screening (NIPT) and Preimplantation Testing
  • Rare Disease Testing
  • Direct-to-Consumer Testing

Rare Disease Testing Segment to Dominate the Hereditary Genetic Testing Market (by Other Genetic Testing Type)

Based on other genetic testing type, the global hereditary genetic testing market was led by the rare disease testing segment, which held a 39.13% share in 2023. This substantial market share highlights the crucial role of genetic testing in diagnosing rare diseases, which often have a hereditary component. Genetic tests for rare diseases are essential for identifying specific mutations that may not be well understood or easily diagnosed through traditional methods. The dominance of the rare disease testing segment reflects the growing awareness and need for precise diagnostic tools to manage and treat these conditions effectively.

Segmentation 8: by Application Area

  • Academic and Research
  • Clinical Diagnostics, Monitoring and Screening
  • Drug Discovery

Clinical Diagnostics Segment to Dominate the Hereditary Genetic Testing Market (by Application Area)

Based on application area, the global hereditary genetic testing market was led by the clinical diagnostics segment, which held a 40.99% share in 2023. This substantial market share highlights the crucial role of clinical diagnostics in hereditary genetic testing, emphasizing the importance of accurate and early detection of genetic conditions for effective medical intervention. The dominance of the clinical diagnostics segment reflects the growing reliance on genetic tests to guide clinical decisions and personalize treatment plans, ultimately improving patient outcomes. This trend underscores the significance of integrating advanced genetic diagnostics into routine clinical practice to address the rising prevalence of hereditary disorders and enhance healthcare delivery.

Segmentation 9: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Netherlands
    • Rest-of-Europe
  • Asia-Pacific
    • Japan
    • India
    • China
    • Singapore
    • Australia
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa

The hereditary genetic testing market in the North America region is expected to witness a significant growth rate of 11.41% during the forecast period. This notable growth can be attributed to several key factors. Continuous advancements in genetic testing technologies are enhancing the accuracy and accessibility of hereditary genetic tests, driving market expansion. Growing awareness about the importance of genetic testing for early diagnosis and management of inherited conditions is leading to higher adoption rates among healthcare providers and patients. Supportive government policies and funding for genetic research and testing are fostering a conducive environment for market growth in the region. However, the Asia-Pacific region is expected to reach $21.97 billion in 2033 from $5.36 billion in 2023, at a CAGR of 15.18% during the forecast period 2024-2033.

Recent Developments in the Hereditary Genetic Testing Market

  • In April 2024, Agilent Technologies, Inc. received Class C Certification under the European Union In Vitro Diagnostic Regulation (IVDR) for its GenetiSure Dx Postnatal Assay. The GenetiSure Dx Postnatal Assay device helps clinical geneticists detect genetic anomalies earlier and more accurately than traditional methods.
  • In April 2024, Konica Minolta, Inc. (Ambry Genetics) initiated the Inter-Organization Cancer Genetics Clinical Evidence Coalition (INTERACT) Collaboration with the aim of promoting hereditary cancer testing. The coalition's objective is to enhance access to genetic testing for individuals affected by or at risk of hereditary cancers. Additionally, the coalition endeavors to influence medical professionals and industry guidelines pertaining to such testing.
  • In April 2024, Quest Diagnostics Incorporated and Broad Clinical Labs revealed a research partnership aimed at showcasing the clinical utility of whole genome sequencing (WGS) as the primary genetic test for diagnosing developmental delay disorders after birth. The collaboration aims to illustrate that WGS can offer insights obtained from a single blood test that is at least as clinically precise as the multiple conventional tests typically employed by healthcare providers to diagnose patients.
  • In January 2024, Myriad Genetics, Inc. disclosed its definitive agreement to acquire specific assets from the Intermountain Precision Genomics (IPG) laboratory division. These assets include the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory located in St. George, Utah, where the Precise Tumor Test is presently conducted.
  • In January 2024, Natera, Inc. disclosed the acquisition of specific assets about Invitae's non-invasive prenatal screening and carrier screening business. Natera, Inc. has already provided an initial payment of $10 million, with an additional $42.5 million pending, to be disbursed in cash, milestone payments, and litigation credits. The reproductive health portfolio comprises genetic tests offering non-invasive prenatal screening and carrier screening.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Rising Prevalence of Genetic Disorders along with Rare Diseases: Genetic diseases stem from abnormalities within an individual's DNA. They can arise through inheritance from one or both parents or manifest due to spontaneous genetic mutations. These conditions may result from a mutation in a single gene (monogenic), a chromosomal alteration involving an abnormal number of copies, or complex disorders influenced by the combined effects of multiple genes (polygenic). Next-generation sequencing techniques are widely used for the diagnosis of genetic diseases. Increasing widespread use of NGS in diagnostic laboratories has enhanced the accuracy of genetic diagnostics with high consistency.

Market Challenges:

Privacy and Ethical Concerns Due to Increased Risk of Security Breaches: Privacy and ethical concerns have become significant challenges in the hereditary genetic testing market, especially with the increasing risk of security breaches. As genetic data contain detailed personal information, they have become a prime target for cyberattacks. The implications of such breaches are profound, considering the sensitivity of genetic information, which can reveal predispositions to certain diseases and other personal attributes.

Market Opportunities:

Rise of Direct-to-Consumer (DTC) Testing Services: The increasing number of direct-to-consumer (DTC) hereditary genetic tests is set to significantly influence the global hereditary genetic testing market. As defined by the U.S. FDA, DTC tests allow consumers to bypass traditional healthcare systems by sending specimens directly to testing companies. This accessibility is appealing as it eliminates many of the barriers associated with traditional genetic testing, such as the need for a healthcare provider's referral, potentially lengthy wait times, and sometimes prohibitive costs. Companies such as 23andMe have pioneered this approach, becoming the first to obtain FDA approval for such tests, signaling a robust regulatory framework that supports consumer safety while encouraging innovation.

How can this report add value to an organization?

Product/Innovation Strategy: The global hereditary genetic testing market has been extensively segmented based on various categories, such as technology, product, sample type, application area, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: Partnerships, alliances, and collaborations accounted for the maximum number of key developments, i.e., nearly 37.14% of the total developments in the global hereditary genetic testing market were between January 2020 and April 2024.

Competitive Strategy: The global hereditary genetic testing market has numerous established players with product portfolios. Key players in the global hereditary genetic testing market analyzed and profiled in the study involve established players offering products for hereditary genetic testing.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • The base year considered for the calculation of the market size is 2023. A historical year analysis has been done for the period FY2019-FY2021. The market size has been estimated for FY2024 and projected for the period FY2024-FY2033.
  • The scope of this report has been carefully derived based on interactions with experts in different companies across the world. This report provides a market study of upstream and downstream products of hereditary genetic testing.
  • The market contribution of hereditary genetic testing is anticipated to be launched in the future and has been calculated based on the historical analysis of the solutions.
  • Revenues of the companies have been referenced from their annual reports for FY2022 and FY2023. For private companies, revenues have been estimated based on factors such as inputs obtained from primary research, funding history, market collaborations, and operational history.
  • The market has been mapped based on the available hereditary genetic testing solutions. All the key companies with significant offerings in this field have been considered and profiled in this report.

Primary Research:

The primary sources involve industry experts in hereditary genetic testing, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding the competitive landscape and business model
  • Current and proposed production values of a product by market players
  • Validation of the numbers of the different segments of the market in focus
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • Segmentations and percentage shares
  • Data for market value
  • Key industry trends of the top players of the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Agilent Technologies, Inc.
  • BGI Group (Beijing Genomics Institute (BGI))
  • Centogene AG
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Konica Minolta, Inc. (Ambry Genetics)
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific Inc.

Table of Contents

Executive Summary

Scope and Definition

1 Hereditary Genetic Testing: Industry Outlook

  • 1.1 Current State of Hereditary Genetic Testing
  • 1.2 Market Footprint and Future Potential
  • 1.3 Trends: Current and Future Impact Assessment
    • 1.3.1 Increasing Demand for Direct-to-consumer Testing
    • 1.3.2 Increasing Launch of Innovative Products and Regulatory Approvals in Genetic Testing Ecosystem
  • 1.4 R&D Review
    • 1.4.1 Patent Filing Trend (by Year, Country)
  • 1.5 Total Addressable Market and Penetration
  • 1.6 Legal and Regulatory Framework
    • 1.6.1 U.S.
    • 1.6.2 Europe
      • 1.6.2.1 Germany
      • 1.6.2.2 France
      • 1.6.2.3 Italy
    • 1.6.3 Asia-Pacific
      • 1.6.3.1 China
      • 1.6.3.2 Japan
      • 1.6.3.3 Australia
  • 1.7 Reimbursement Scenario
  • 1.8 Market Dynamics
    • 1.8.1 Market Drivers
      • 1.8.1.1 Rising Prevalence of Genetic Disorders along with Rare Diseases
      • 1.8.1.2 Increasing Inorganic Growth Activities in the Field of Hereditary Genetic Testing
      • 1.8.1.3 Increasing Number of Hereditary Genetic Tests
    • 1.8.2 Market Restraints
      • 1.8.2.1 High Cost Associated with Testing
      • 1.8.2.2 Shortage of Genetic Counselors
    • 1.8.3 Market Opportunities
      • 1.8.3.1 Expansion into Emerging Markets

2 Global Hereditary Genetic Testing Market (by Product)

  • 2.1 Overview
    • 2.1.1 Kits and Consumables
    • 2.1.2 Services

3 Global Hereditary Genetic Testing Market (by Sample Type)

  • 3.1 Overview
    • 3.1.1 Tumor Tissue
    • 3.1.2 Bone Marrow
    • 3.1.3 Saliva
    • 3.1.4 Blood
    • 3.1.5 Other Sample Types

4 Global Hereditary Genetic Testing Market (by Technology)

  • 4.1 Overview
    • 4.1.1 Next-Generation Sequencing (NGS)
    • 4.1.2 Polymerase Chain Reaction (PCR)
    • 4.1.3 Immunohistochemistry (IHC)
    • 4.1.4 In-Situ Hybridization (ISH)
    • 4.1.5 Microarray Techniques
    • 4.1.6 Other Technologies

5 Global Hereditary Genetic Testing Market (by Genetic Testing Type)

  • 5.1 Overview
  • 5.2 Cardiology
    • 5.2.1 Cardiomyopathy
    • 5.2.2 Aortopathy
    • 5.2.3 Arrhythmia
    • 5.2.4 Other Cardiology Hereditary Genetic Testing
  • 5.3 Oncology
    • 5.3.1 Breast Cancer
    • 5.3.2 Lung Cancer
    • 5.3.3 Prostate Cancer
    • 5.3.4 Colorectal Cancer
    • 5.3.5 Melanoma
    • 5.3.6 Other Oncology Hereditary Genetic Testing
  • 5.4 Neurology
    • 5.4.1 Epilepsy
    • 5.4.2 Neurodegenerative Disorders
    • 5.4.3 Neuromuscular Disorders
    • 5.4.4 Other Neurology Hereditary Genetic Testing
  • 5.5 Other Genetic Testing Type
    • 5.5.1 Newborn Screening
    • 5.5.2 Prenatal Screening (NIPT) and Preimplantation Testing
    • 5.5.3 Rare Disease Testing
    • 5.5.4 Direct-to-Consumer Testing

6 Global Hereditary Genetic Testing Market (by Application Area)

  • 6.1 Overview
    • 6.1.1 Academic and Research
    • 6.1.2 Clinical Diagnostics, Monitoring and Screening
    • 6.1.3 Drug Discovery

7 Region

  • 7.1 Drivers and Restraints
  • 7.2 North America
    • 7.2.1 Regional Overview
    • 7.2.2 Driving Factors for Market Growth
    • 7.2.3 Factors Challenging the Market
    • 7.2.4 U.S.
    • 7.2.5 Canada
  • 7.3 Europe
    • 7.3.1 Regional Overview
    • 7.3.2 Driving Factors for Market Growth
    • 7.3.3 Factors Challenging the Market
    • 7.3.4 France
    • 7.3.5 Germany
    • 7.3.6 U.K.
    • 7.3.7 Spain
    • 7.3.8 Netherlands
    • 7.3.9 Rest-of-Europe
  • 7.4 Asia-Pacific
    • 7.4.1 Regional Overview
    • 7.4.2 Driving Factors for Market Growth
    • 7.4.3 Factors Challenging the Market
    • 7.4.4 China
    • 7.4.5 India
    • 7.4.6 Australia
    • 7.4.7 Japan
    • 7.4.8 Singapore
    • 7.4.9 Rest-of-Asia-Pacific
  • 7.5 Latin America
    • 7.5.1 Regional Overview
    • 7.5.2 Driving Factors for Market Growth
    • 7.5.3 Factors Challenging the Market
    • 7.5.4 Brazil
    • 7.5.5 Mexico
    • 7.5.6 Rest-of-Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 Regional Overview
    • 7.6.2 Driving Factors for Market Growth
    • 7.6.3 Factors Challenging the Market

8 Markets - Competitive Benchmarking & Company Profiles

  • 8.1 Competitive Landscape
    • 8.1.1 Key Strategies and Development
      • 8.1.1.1 Mergers and Acquisitions
      • 8.1.1.2 Product Launches
      • 8.1.1.3 Synergistic Activities
      • 8.1.1.4 Business Expansion Activities and Others
    • 8.1.2 Company Share Analysis
  • 8.2 Company Profiles
    • 8.2.1 Agilent Technologies, Inc.
      • 8.2.1.1 Overview
      • 8.2.1.2 Top Products/Product Portfolio
      • 8.2.1.3 Top Competitors
      • 8.2.1.4 Target Customers
      • 8.2.1.5 Key Personnel
      • 8.2.1.6 Analyst View
    • 8.2.2 BGI Group (Beijing Genomics Institute (BGI))
      • 8.2.2.1 Overview
      • 8.2.2.2 Top Products
      • 8.2.2.3 Top Competitors
      • 8.2.2.4 Key Personnel
      • 8.2.2.5 Analyst View
    • 8.2.3 Centogene AG
      • 8.2.3.1 Overview
      • 8.2.3.2 Top Products/Product Portfolio
      • 8.2.3.3 Top Competitors
      • 8.2.3.4 Key Personnel
      • 8.2.3.5 Analyst View
    • 8.2.4 Eurofins Scientific SE
      • 8.2.4.1 Overview
      • 8.2.4.2 Top Products
      • 8.2.4.3 Top Competitors
      • 8.2.4.4 Key Personnel
      • 8.2.4.5 Analyst View
    • 8.2.5 F. Hoffmann-La Roche Ltd
      • 8.2.5.1 Top Products
      • 8.2.5.2 Top Competitors
      • 8.2.5.3 Key Personnel
      • 8.2.5.4 Analyst View
    • 8.2.6 Illumina, Inc.
      • 8.2.6.1 Overview
      • 8.2.6.2 Top Products/Product Portfolio
      • 8.2.6.3 Top Competitors
      • 8.2.6.4 Key Personnel
      • 8.2.6.5 Analyst View
    • 8.2.7 Konica Minolta, Inc. (Ambry Genetics)
      • 8.2.7.1 Overview
      • 8.2.7.2 Top Products/Product Portfolio
      • 8.2.7.3 Top Competitors
      • 8.2.7.4 Key Personnel
      • 8.2.7.5 Analyst View
    • 8.2.8 Laboratory Corporation of America Holdings
      • 8.2.8.1 Overview
      • 8.2.8.2 Top Products/Product Portfolio
      • 8.2.8.3 Top Competitors
      • 8.2.8.4 Key Personnel
      • 8.2.8.5 Analyst View
    • 8.2.9 Myriad Genetics, Inc.
      • 8.2.9.1 Overview
      • 8.2.9.2 Top Products/Product Portfolio
      • 8.2.9.3 Top Competitors
      • 8.2.9.4 Key Personnel
      • 8.2.9.5 Analyst View
    • 8.2.10 Revvity, Inc. (PerkinElmer, Inc.)
      • 8.2.10.1 Overview
      • 8.2.10.2 Top Products/Product Portfolio
      • 8.2.10.3 Top Competitors
      • 8.2.10.4 Key Personnel
      • 8.2.10.5 Analyst View
    • 8.2.11 Quest Diagnostics Incorporated
      • 8.2.11.1 Overview
      • 8.2.11.2 Top Products/Product Portfolio
      • 8.2.11.3 Top Competitors
      • 8.2.11.4 Key Personnel
      • 8.2.11.5 Analyst View
    • 8.2.12 Thermo Fisher Scientific, Inc.
      • 8.2.12.1 Overview
      • 8.2.12.2 Top Products/Product Portfolio
      • 8.2.12.3 Top Competitors
      • 8.2.12.4 Key Personnel
      • 8.2.12.5 Analyst View
    • 8.2.13 Emerging Companies in the Hereditary Genetic Testing Market

9 Research Methodology

  • 9.1 Data Sources
    • 9.1.1 Primary Data Sources
    • 9.1.2 Secondary Data Sources
    • 9.1.3 Data Triangulation
  • 9.2 Market Estimation and Forecast
  • 9.3 Criteria for Company Profiling

List of Figures

  • Figure 1: Global Hereditary Genetic Testing Market, by Region, $Billion, 2023, 2027, and 2033
  • Figure 2: Global Hereditary Genetic Testing Market (by Technology), $Billion, 2023 and 2033
  • Figure 3: Global Hereditary Genetic Testing Market (by Product), $Billion, 2023 and 2033
  • Figure 4: Global Hereditary Genetic Testing Market (by Sample Type), $Billion, 2023 and 2033
  • Figure 5: Global Hereditary Genetic Testing Market (by Application Area), $Billion, 2023 and 2033
  • Figure 6: Global Hereditary Genetic Testing Market (by Testing Type), $Billion, 2023 and 2033
  • Figure 7: Key Events to Keep Track of in the Hereditary Genetic Testing Market
  • Figure 8: Types of Hereditary Genetic Tests
  • Figure 9: Global Hereditary Genetic Testing Market, Patent Analysis (by Year), January 2021-April 2024
  • Figure 10: Global Hereditary Genetic Testing Market, Patent Analysis (by Country), January 2021-April 2024
  • Figure 11: Global Hereditary Genetic Testing Market Scenario, 2023
  • Figure 12: Analysis of Market Navigating Factors, 2024-2033
  • Figure 13: Rising Prevalence of Genetic Disorders
  • Figure 14: Prevalence of a Few Rare Diseases
  • Figure 15: Few Major Inorganic Growth Activities in the Hereditary Genetic Testing Market
  • Figure 16: Number of Hereditary Genetic Tests Registered on Genetic Testing Registry, by Year
  • Figure 17: Need for More Genetic Counselors
  • Figure 18: Key Expansions in the Past Few Years
  • Figure 19: U.S. Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 20: Canada Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 21: France Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 22: Germany Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 23: U.K. Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 24: Spain Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 25: Netherlands Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 26: Rest-of-Europe Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 27: China Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 28: India Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 29: Australia Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 30: Japan Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 31: Singapore Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 32: Rest-of-Asia-Pacific Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 33: Brazil Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 34: Mexico Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 35: Rest-of-Latin America Hereditary Genetic Testing Market, $Billion, 2022-2033
  • Figure 36: Number of Mergers and Acquisitions (by Company), January 2021-April 2024
  • Figure 37: Number of Product Launches (by Company), January 2021-April 2024
  • Figure 38: Synergistic Activities Share (by Company), January 2021-April 2024
  • Figure 39: Business Expansion Activities Share (by Company), January 2021-April 2024
  • Figure 40: Global Hereditary Genetic Testing Market, Company Revenue Share Analysis, $Billion, 2023
  • Figure 41: Data Triangulation
  • Figure 42: Top-Down and Bottom-Up Approach
  • Figure 43: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Opportunities across Regions
  • Table 3: Global Hereditary Genetic Testing Market, Product Launches and Regulatory Approvals
  • Table 4: Regulatory Bodies Governing Hereditary Genetic Testing
  • Table 5: Global Hereditary Genetic Testing Market (by Product), $Billion, 2022-2033
  • Table 6: Global Hereditary Genetic Testing Market (by Sample Type), $Billion, 2022-2033
  • Table 7: Global Hereditary Genetic Testing Market (by Technology), $Billion, 2022-2033
  • Table 8: Global Hereditary Genetic Testing Market (by Oncology Genetic Testing Type), $Billion, 2022-2033
  • Table 9: Global Hereditary Genetic Testing Market (by Cardiology Genetic Testing Type), $Billion, 2022-2033
  • Table 10: Global Hereditary Genetic Testing Market (by Neurology Genetic Testing Type), $Billion, 2022-2033
  • Table 11: Global Hereditary Genetic Testing Market (by Other Genetic Testing Type), $Billion, 2022-2033
  • Table 12: Global Hereditary Genetic Testing Market (by Application Area), $Billion, 2022-2033
  • Table 13: North America Hereditary Genetic Testing Market (by Genetic Testing Type), $Billion, 2022-2033
  • Table 14: Europe Hereditary Genetic Testing Market (by Genetic Testing Type), $Billion, 2022-2033
  • Table 15: Asia-Pacific Hereditary Genetic Testing Market (by Genetic Testing Type), $Billion, 2022-2033
  • Table 16: Latin America Hereditary Genetic Testing Market (by Genetic Testing Type), $Billion, 2022-2033
  • Table 17: Middle East and Africa Genetic Testing Market (by Genetic Testing Type), $Billion, 2022-2033
  • Table 18: Emerging Companies in Hereditary Genetic Testing Market